Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 12-Month High After Analyst Upgrade

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) reached a new 52-week high during mid-day trading on Monday after Citigroup raised their price target on the stock from $45.00 to $50.00. Citigroup currently has a buy rating on the stock. Kiniksa Pharmaceuticals International traded as high as $39.57 and last traded at $39.37, with a volume of 280711 shares changing hands. The stock had previously closed at $38.64.

Other research analysts have also recently issued research reports about the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, October 8th. Wedbush lifted their price objective on shares of Kiniksa Pharmaceuticals International from $38.00 to $44.00 and gave the company an “outperform” rating in a report on Monday, October 13th. Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Friday, October 3rd. Wells Fargo & Company lifted their price objective on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the company an “overweight” rating in a report on Thursday, September 25th. Finally, Zacks Research cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $46.86.

Insider Activity at Kiniksa Pharmaceuticals International

In other news, insider Ross Moat sold 3,523 shares of the business’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $35.31, for a total transaction of $124,397.13. Following the completion of the sale, the insider owned 9,415 shares of the company’s stock, valued at $332,443.65. The trade was a 27.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Michael R. Megna sold 11,000 shares of the business’s stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $34.84, for a total transaction of $383,240.00. Following the sale, the chief accounting officer directly owned 38,011 shares of the company’s stock, valued at $1,324,303.24. This represents a 22.44% decrease in their position. The disclosure for this sale can be found here. Insiders sold 596,839 shares of company stock worth $20,357,964 over the last three months. Company insiders own 53.48% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals International

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Rubric Capital Management LP grew its stake in Kiniksa Pharmaceuticals International by 15.6% during the 2nd quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock valued at $108,184,000 after acquiring an additional 526,567 shares in the last quarter. Vanguard Group Inc. grew its stake in Kiniksa Pharmaceuticals International by 4.7% during the 1st quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company’s stock valued at $74,606,000 after acquiring an additional 151,604 shares in the last quarter. Acadian Asset Management LLC grew its stake in Kiniksa Pharmaceuticals International by 22.6% during the 2nd quarter. Acadian Asset Management LLC now owns 1,267,989 shares of the company’s stock valued at $35,067,000 after acquiring an additional 233,668 shares in the last quarter. Qube Research & Technologies Ltd grew its stake in Kiniksa Pharmaceuticals International by 277.8% during the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after acquiring an additional 653,236 shares in the last quarter. Finally, Millennium Management LLC grew its stake in Kiniksa Pharmaceuticals International by 8.7% during the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after acquiring an additional 67,452 shares in the last quarter. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Stock Performance

The company has a market cap of $2.89 billion, a PE ratio of 974.99 and a beta of 0.16. The firm’s 50 day moving average is $35.98 and its 200-day moving average is $29.95.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The company had revenue of $156.80 million during the quarter, compared to analysts’ expectations of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.